Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC ...Middle East

SEONGNAM, South Korea and NEWTON, Mass., Oct. 30, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced that the company has initiated the Phase 1/2 clinical trial...

Hence then, the article about bridge biotherapeutics announces initiation of phase 1 2 clinical trial of bbt 207 in egfr mutant nsclc was published today ( Tuesday 31/10/2023 - 02:05 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC )

Also on site :

• From collapse fears to resilience: How Russia reshaped its economy by the end of 2025
• Russian MOD shows map of Ukrainian drone attack on Putin’s residence
• Advantech Unveils Next-Generation Edge AI Compute Solutions Powered by Qualcomm Dragonwing IQ-X Series